Azitra, Inc. (AZTR) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Azitra, Inc. (AZTR) closed at USD 0.07 on 2026-10-14, a change of -85.4 % over the past year, with a market capitalization of USD 4.33M.
Azitra, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.07 |
| 2026-10-13 | 0.07 |
| 2026-10-12 | 0.12 |
| 2026-10-09 | 0.13 |
| 2026-10-08 | 0.13 |
| 2026-10-07 | 0.13 |
| 2026-10-06 | 0.13 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Azitra, Inc. key figures
- Previous close
- USD 0.07 (2026-10-14)
- 1-year change
- -85.4 %
- Market cap
- USD 4.33M
- Enterprise value
- USD -1.98M
- P/E ratio (trailing)
- -0.26
- P/E ratio (forward)
- -0.14
- EPS (trailing)
- -0.28
- EPS (forward)
- -0.52
- PEG ratio
- n/a
- Price to book
- 0.59
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.34
- Employees
- 13
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Azitra, Inc.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Azitra, Inc. and compare it with other stocks.
Analyze AZTRAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Azitra, Inc. shares.